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Autoantibody levels are associated 
with acute kidney injury, anemia 
and post-discharge morbidity and 
mortality in Ugandan children with 
severe malaria
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Ruth namazzi3, Benson ouma5, paul Bangirana6, Richard idro3,7, Andrew L. Schwaderer2, 
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Autoantibodies targeting host antigens contribute to autoimmune disorders, frequently occur during 
and after infections and have been proposed to contribute to malaria-induced anemia. We measured 
anti-phosphatidylserine (PS) and anti-DNA antibody levels in 382 Ugandan children prospectively 
recruited in a study of severe malaria (SM). High antibody levels were defined as antibody levels 
greater than the mean plus 3 standard deviations of community children (CC). We observed increases 
in median levels of anti-pS and anti-DnA antibodies in children with SM compared to cc (p < 0.0001 
for both). children with severe malarial anemia were more likely to have high anti-pS antibodies than 
children with cerebral malaria (16.4% vs. 7.4%), p = 0.02. Increases in anti-PS and anti-DNA antibodies 
were associated with decreased hemoglobin (p < 0.05). A one-unit increase in anti-DNA antibodies 
was associated with a 2.99 (95% CI, 1.68, 5.31) increase odds of acute kidney injury (AKI) (p < 0.0001). 
elevated anti-pS and anti-DnA antibodies were associated with post-discharge mortality (p = 0.031 
and p = 0.042, respectively). Children with high anti-PS antibodies were more likely to have multiple 
hospital readmissions compared to children with normal anti-pS antibody levels (p < 0.05). SM is 
associated with increased autoantibodies against pS and DnA. Autoantibodies were associated with 
anemia, AKI, post-discharge mortality, and hospital readmission.
Malaria is an intravascular parasitic disease caused by infection with Plasmodium. Plasmodium falciparum is 
the most prevalent malaria species in Africa. In 2017 there were 219 million cases and 435,000 global malaria 
deaths with 61% of deaths occurring in children less than five years of age1. Two common complications of severe 
malaria (SM) are severe malarial anemia (SMA) and cerebral malaria (CM). SMA is life-threatening and accounts 
for over half of childhood malaria deaths in Africa, and occurs through multiple mechanisms, including: direct 
destruction of infected RBCs, clearance of infected and uninfected RBCs, and insufficient bone marrow produc-
tion (reviewed in2). Death is preventable in SMA if children receive an appropriate transfusion3,4. CM is char-
acterized by an unrousable coma with no other identifiable cause, and typically has a mortality rate of 18–21%5. 
Reported mortality in African children with SM was 10% in the AQUAMAT study and ranged from 4–15% across 
11 sites in 9 different African countries4.
Elevations in autoantibodies targeting self antigens, such as DNA, are well recognized in autoimmune disor-
ders like systemic lupus erythematosus (SLE) and are used for diagnosis, prognosis, and understanding disease 
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pathogenesis6,7. Autoantibodies have been associated with complications in a number of infections8,9, and auto-
immunity during and after infection is frequently reported in diseases associated with systemic inflammatory 
responses— including malaria10,11. While autoantibodies in malaria were initially attributed to non-specific poly-
clonal immune activation12, more recent studies demonstrate direct parasite induced secretion of autoantibodies 
in the host13.
Malaria shares clinical features with autoimmune disorders, including autoimmune anemia. Using a mouse 
model, it was observed that anti-phopsphatidylserine (PS) antibodies promote anemia during malaria through 
the binding to PS exposed in uninfected erythrocytes which facilitates their clearance14. It was also observed that 
levels of anti-PS antibodies are correlated with malarial anemia in patients14,15. Although autoantibodies have 
been reported in experimental models of malaria and patient populations16–18, few studies have investigated the 
relationship between autoantibodies and SM complications. Acute kidney injury (AKI) is a common complica-
tion in pediatric SM associated with significant morbidity and mortality4,19,20, but the pathogenesis is not well 
understood.
Given reports of elevated autoantibodies in SM and clinical similarities between malaria and autoimmune 
disorders, we sought to evaluate the relationship between anti-PS and anti-DNA antibodies in children with SM. 
We hypothesized children with SM would have elevated autoantibodies associated with complications on admis-
sion including anemia and AKI. In this prospective cohort study, we measured admission anti-PS and anti-DNA 
autoantibodies in Ugandan children with SM and evaluated whether autoantibodies were associated with disease 
severity and outcomes over two years follow-up.
Methods
Study population. The study was performed at Mulago Hospital, Kampala, Uganda between 2008 and 2013. 
All eligible children between 18 months and 12 years of age were enrolled. CM was defined as: (1) coma (Blantyre 
Coma Score (≤2); (2) P. falciparum on blood smear; and (3) no other known cause of coma (e.g., meningitis, a 
prolonged postictal state or hypoglycemia-associated coma reversed by glucose infusion). SMA was defined as 
presence of P. falciparum on blood smear in children with a hemoglobin ≤5 g/dL. Additional exclusion criteria 
for children with SMA included: (1) impaired consciousness on physical exam; (2) other clinical evidence of 
central nervous system (CNS) disease; or (3) >1 seizure prior to admission. Children with SM were managed 
according to Ugandan Ministry of Health treatment guidelines at the time of the study as described21.
Community children (CC) were recruited from the nuclear family, extended family, or household compound 
area of children with SM who were between the ages of 18 months and 12 years, and within 1 year of age of the 
household participant with CM or SMA. We excluded children who lived further than 50 km from Mulago and 
children for whom the primary caregiver reported: (1) chronic illness requiring medical care, (2) history of devel-
opmental delay, (3) history of coma, head trauma, or cerebral palsy, or (4) history of hospitalization for malnutri-
tion. Additional exclusion criteria for CC included: (1) illness requiring medical care within the previous 4 weeks 
or active illness; or (2) major medical or neurological abnormalities on screening physical exam.
Children were followed for two years and were asked to return to the hospital for neurodevelopmental follow 
up assessment at 6, 12, and 24 months. Children were also asked to return to hospital for any illness requiring 
treatment, and received free care and transportation reimbursement for all hospital visits.
Assessment of acute kidney injury. The bedside Schwartz equation was used to estimate kidney function 
where the estimated glomerular filtration rate (eGFR) = (k*height)/Cr, where k = 0.413). Acute kidney injury 
(AKI) was defined using the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines22 using on admis-
sion creatinine levels and predicted baseline creatinine from the CC23. A 1.5-fold increase in creatinine from 
baseline was defined as AKI. AKI was further staged as follows: stage 1, 1.5–1.9x increase from baseline; stage 
2, 2.0–2.9 increase in creatinine from baseline; stage 3, ≥3.0x increase in creatinine from baseline or an eGFR 
<35 mL/min/1.73 m2. Data on urine output or proteinuria are not available.
Antibody testing. Antibodies against malaria-specific antigens were measured using a multiplex magnetic 
bead assay as previously described24, and data expressed as arbitrary units (AU). The recombinant P. falciparum 
antigens used for testing were apical membrane antigen-1 (AMA-1, full length ectodomain FVO strain; pro-
vided by David E. Lanar, Walter Reed Army Institute for Research); glutamate rich protein (GLURP, conserved 
non-repeat N-terminal region, amino acids 25–514, R0; provided by Michael Theisen, Statens Seruminstitut, 
Copenhagen, Denmark); merozoite surface protein-1 (MSP-142 FVO strain; provided by David Narum, National 
Institutes of Health); and circumsporozoite protein (CSP, (NANP)5 repeat peptide; Sigma Genosys). Magnetic 
beads were coupled to four P. falciparum antigens: AMA-1 (bead region, 44; coating concentration, 2 μg), CSP 
(bead region, 64; coating concentration, 10 μg), GLURP (bead region, 26; coating concentration, 0.5 μg) and 
MSP-1 (bead region, 36; coating concentration, 1 μg). Serum samples were diluted 1:100 in serum dilution buffer, 
and combined 1:1 with beads to produce a final dilution of 1:200. A minimum of 50 beads/region were counted 
per sample and median fluorescence intensity was used as the output value. The assay used a pool of plasma sam-
ples from highly exposed Ugandan individuals (n = 30) and North American donor samples without a history of 
malaria exposure (n = 9).
To measure autoimmune antibodies, Costar 3750 96-well ELISA plates were coated with PS (Sigma) at 20 μg/ml 
in 200-proof Molecular Biology ethanol or calf thymus DNA (Sigma) at 10 μg/ml in PBS. Plates were allowed 
to evaporate during 16 h at 4 °C. Plates were washed 3 times with PBS 0.05% Tween-20 and then blocked for 1 h 
with PBS 3% BSA. Plasma from patients or control was diluted at 1:100 in blocking buffer and incubated for 2 h 
at 37 °C. Plates were washed again 3 times and incubated with a polyclonal sheep anti-human IgG-HRP diluted 
1:2000 (GE Healthcare) for 1 h at 37 °C. Plates were washed 3 more times and developed using TMB substrate 
(BD Biosciences). The reaction was stopped using Stop buffer (Biolegend) and absorbance read at 450 nm. The 
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mean OD at 450 nm from replicate wells was compared with reference serum from a Colombian P. vivax patient 
previously identified as high responder for anti-PS IgG antibodies to calculate relative units (RU). To determine 
cutoff values for anti-PS and anti-DNA antibodies, antibody reactivity was determined using the CC and a value 
above the group mean plus 3 standard deviations was considered to have high antibody levels.
Statistical analysis. Data were analyzed using STATA v14.0 (StataCorp., 2015) and GraphPad Prism v7. 
Unadjusted comparisons for continuous measures using the Wilcoxon rank sum test or categorical measures 
using Pearson’s Chi square or Fisher’s exact test as appropriate. Logistic or linear regression was used to evaluate 
the association between autoantibody levels and SM complications. Logistic regression was used to assess the 
relationship between antibody levels and disease outcome adjusting for child age. A non-parametric test for trend 
was used to evaluate the association between autoantibodies across stages of AKI. Spearman’s rho was used to 
evaluate correlations between autoantibody levels and continuous laboratory or biochemical measures of malaria 
disease severity. Holm’s correction was used to adjust for multiple comparisons.
ethics statement. Written informed consent was obtained from parents or guardians of all study partici-
pants. Ethical approval was granted by the Institutional Review Boards for human studies at Makerere University 
School of Medicine and the University of Minnesota. All research was performed in accordance with relevant 
guidelines and regulations.
Meetings where information has previously been presented. American Society of Microbiology, 
2018 meeting, Atlanta, Georgia. Presenter: Juan Rivera-Correa (poster).
Results
In total, 382 children with samples available for autoantibody testing were included in the study (Fig. 1). The 
demographic characteristics of the population are presented in Table 1. Differences in enrollment characteristics 
of children included versus those not included are compared in Supplementary Table 1. Overall, children with 
SM were younger, and had lower weight-for-height and weight-for-age z scores than CC (Table 1). Children with 
malaria had laboratory values consistent with a diagnosis of SM, including: lower hemoglobin and platelet counts, 
higher white blood cell counts, and evidence of renal dysfunction (higher creatinine and BUN) and hemolysis 
(elevated LDH and total bilirubin) (Table 1).
Within the SM group, children with CM had higher median hemoglobin levels, lower white blood cell and 
platelet counts, and higher parasite biomass compared to children with SMA (adjusted p < 0.05) (Table 1). We 
further characterized the differences between children with CM and SMA based on the number of WHO severe 
malaria criteria present (Supplementary Table 2). Children with CM were more likely to be prostrate, have 
repeated convulsions, and hyperparasitemia (adjusted p < 0.05) compared to children with SMA (Supplementary 
Table 2). On the other hand, children with SMA were more likely to have jaundice (adjusted p < 0.05). Overall, 
children with CM had more severe malaria criteria present than children with SMA (Supplementary Table 2).
Autoantibody levels are elevated in children with severe malaria compared to cc. We compared 
anti-PS and anti-DNA antibody levels at enrollment in children with SM and CC. Children with CM and SMA 
had higher median levels of circulating anti-PS and anti-DNA autoantibodies compared to CC (adjusted p < 0.05, 
Fig. 2A,B). Further, children with SM were more likely to have high autoantibodies than CC (anti-PS antibod-
ies, 13.0% in SM vs. 3.0% in CC vs. p = 0.02; anti-DNA antibodies, 12.7% in SM vs. 1.5% in CC vs. p = 0.008). 
Children with SM had a 4.77 (95% CI: 1.12, 20.24, p = 0.034) and 9.42 (95% CI: 1.27, 69.79, p = 0.028) fold 
increase in odds of a high anti-PS and anti-DNA test compared to CC. The relationship between anti-PS and 
anti-DNA antibodies are shown in Fig. 2C. A total of 64 children with SM had high autoantibodies: 7.59% for 
anti-PS antibodies alone, 5.38% for both anti-PS and anti-DNA antibodies, and 7.28% for anti-DNA antibodies 
alone.
Relationship between autoantibody levels and severe malaria complications. To determine 
whether autoantibody levels were related to specific malaria complications and laboratory measures of disease 
severity on admission, we compared anti-PS and anti-DNA antibody levels in WHO-defined SM complica-
tions (Table 2). Following correction for multiple comparisons, a one unit increase in relative units of anti-PS 
or anti-DNA antibodies was associated with a −1.04 g/dL (95% CI, −1.63, −0.44) and a −0.95 g/dL (95% CI, 
−1.52, −0.38) decrease in hemoglobin, respectively (adjusted p < 0.05). These results indicate a strong correlation 
between both autoantibodies and anemia. Additionally, a one unit increase in anti-DNA antibodies was associ-
ated with a 2.99 (95% CI, 1.68, 5.31) increase in the odds of AKI, a relationship not seen with anti-PS antibodies 
Figure 1. Flow chart of study participants.
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(Table 2). We repeated the analysis based on whether a child had high autoantibody levels and obtained similar 
results (Supplementary Table 3).
We further explored correlations between autoantibody levels and measures of disease severity in Table 3. 
Both Anti-PS and anti-DNA autoantibodies were positively correlated with creatinine, blood urea nitrogen 
(BUN), and lactate dehydrogenase (LDH) (adjusted p < 0.05). There was no correlation between anti-PS or 
anti-DNA antibody levels and parasite density (anti-DNA antibodies, rho, 0.042, p = 0.463; anti-PS antibodies, 
rho, −0.036, p = 0.526), and a weak correlation between parasite biomass (plasma HRP2) and anti-PS antibody 
levels (Table 3), suggesting the autoimmune response is not being driven by parasite burden.
Relationship between autoantibody levels and kidney function. As anti-DNA antibody levels 
were elevated in AKI, and anti-DNA and anti-PS autoantibodies correlated with creatinine and BUN, we further 
explored the association between autoantibody levels and kidney function. We observed an increase in anti-DNA 
(p < 0.001) and anti-PS (p = 0.028) antibodies across AKI stages using a non-parametric test for trend. There 
was an inverse relationship between anti-PS (rho, −0.206, p = 0.0003) and anti-DNA (rho, −0.283, p < 0.0001) 
antibodies and eGFR in children with SM, but not in CC (anti-PS, rho, −0.254, p = 0.050; anti-DNA, rho, 0.049, 
p = 0.709). There was an increase in the frequency of children with high anti-DNA antibodies across AKI stages 
(no AKI, 9.3%; stage 1 AKI, 16.7%; stage 2 AKI, 18.5%; stage 3 AKI, 41.7%), p = 0.005.
In a sub-set of children who had hemoglobinuria assessed (n = 260), there was an increase in median anti-DNA 
antibodies in children with hemoglobinuria (p = 0.017) compared to children without hemoglobinuria. There was 
no change in anti-PS antibody levels in children based on the presence of hemoglobinuria on admission (p = 0.294). 
There was no relationship between serum albumin levels and autoantibody levels (anti-DNA antibodies, rho, 0.020, 
p = 0.727; anti-PS antibodies, rho, −0.036, p = 0.521) and proteinuria was not assessed.
To determine whether the relationship between reduced glomerular filtration and autoantibodies was related 
to systemic changes in IgG metabolism, we compared levels of antibodies (IgG) to malaria-specific antigens 
representing the blood stage of infection: (i) apical-membrane antigen 1 (AMA-1); (ii) merozoite surface pro-
tein 1 (MSP-1), and (iii) glutamate-rich protein (GLURP); and for the liver stage: (iv) circumsporozoite protein 
(CSP) (Table 4). In children with SM, there were no differences in median levels of antibodies against AMA-1, 
MSP-1, GLURP, or CSP in children with AKI (p > 0.05 for all). In addition, there were no differences levels of 
malaria-specific IgG and eGFR in SM using linear regression (Table 4, p > 0.05 for all).
Finally, we evaluated whether there were changes in malaria-specific antibodies and markers of disease 
severity (Table 4). In contrast to autoimmune antibodies that were positively correlated with several measures 
of disease severity (creatinine, BUN, LDH) (Table 3), there were no clear differences in relationships between 
CC (n = 66) SMA (n = 160) CM (n = 156)
CC vs. Severe 
Malaria P-value
CM vs. SMA 
P-value
Demographics
Age, years 3.9 (2.8, 6.0) 2.7 (2.0, 4.1) 3.5 (2.6, 4.9) 0.001* 0.0004*
Female sex, (%) No. 34 (51.5) 59 (36.9) 66 (42.3) 0.073 0.323
Weight-for-age z score −0.9 (−1.4, −0.1) −1.5 (−2.3, −0.7) −1.2 (−1.9, −0.5) 0.0004* 0.045
Height-for-age z score −1.0 (−1.7, −0.2) −1.0 (−1.8, −0.2) −0.4 (−1.3, 0.7) 0.621 0.006
Weight-for-height z score −0.3 (−0.8, 0.2) −0.9 (−1.8, −0.2) −1.4 (−2.0, −0.5) <0.00001* 0.689
Socioeconomic status score 9 (7, 11) 9 (7, 11) 9 (8, 12) 0.350 0.664
Sickle cell disease, No. (%) 0 (0.0) 17 (10.6) 0 (0.0) 0.052 <0.0001*
HIV positive, No. (%) 1 (1.5) 4 (2.5) 3 (2.0) 1.000 1.000
Laboratory Characteristics
Hemoglobin 11.8 (10.8, 12.6) 3.7 (3.0, 4.5) 6.6 (5.1, 8.5) <0.00001* <0.00001*
WBC 8.8 (6.5, 10.4) 11.7 (8.9, 17.4) 9.4 (6.7, 13.2) <0.00001* <0.00001*
Platelet count 364 (260, 429) 148 (93, 242) 61 (34, 107) <0.00001* <0.00001*
Glucose — 6.4 (4.7, 8.2) 6.7 (5.3, 8.9) — 0.143
Lactate — 5.0 (3.0, 7.8) 3.8 (2.0, 6.8) — 0.009
Creatinine 0.31 (0.26, 0.36) 0.35 (0.27, 0.45) 0.40 (0.30, 0.50) 0.0001* 0.012
BUN 7 (6, 10) 13 (9, 20) 17 (12, 25) <0.00001* 0.002*
Lactate dehydrogenase 261 (234, 304) 765 (607, 1053) 829 (639, 1130) <0.00001* 0.168
Total bilirubin 0.2 (0.1, 0.3) 1.3 (0.7, 2.0) 1.7 (0.9, 3.0) <0.00001* 0.006
Parasite density 0 (0, 0) 34760 (10040, 133720) 41090 (13320, 294620) <0.00001* 0.023
Plasma HRP2 4.8 (4.8, 59.4) 867 (310, 2649) 2658 (1009, 5398) <0.00001* <0.00001*
Table 1. Demographic characteristics of the population at enrollment. Data presented as median (IQR) unless 
otherwise indicated. Abbreviations: community children (CC), severe malarial anemia (SMA), cerebral malaria 
(CM), human immunodeficiency virus (HIV), hemoglobin, g/dL; white blood cell (WBC), ×103/μL; platelet 
count, ×103/μL; glucose, mmol/L; lactate, mmol/L; creatinine, mg/dL; blood urea nitrogen (BUN), mg/dL; 
lactate dehydrogenase, U/L; total bilirubin, mg/dL; parasite density, parasites/uL; plasma histidine rich protein 2 
(HRP2), ng/mL. *Significant following Holm’s adjustment for multiple comparisons (n = 36).
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Figure 2. Anti-PS and anti-DNA antibody levels are elevated in children with severe malaria compared 
to community controls. (A,B) Scatter plot with interquartile range of anti-PS and anti-DNA antibodies in 
Ugandan children with severe malaria (severe malarial anemia (SMA), n = 160; cerebral malaria (CM), n = 156) 
or community children (CC, n = 66) by ELISA expressed as relative units (RU). Samples were considered 
positive for autoantibodies if the relative units (RU) > the mean plus 3 times the standard deviation of the CC. 
The cut-off is indicated by the horizontal line, and positive samples are indicated in red. The group prevalence 
of positive autoantibodies is indicated to the right of the distribution. Differences continuous autoantibody 
levels between groups analyzed using the non-parametric Wilcoxon rank sum test. (C) Scatter plot showing the 
correlation between anti-PS and anti-DNA antibodies in children with severe malaria (rho, 0.558, p < 0.0001) 
showing the percentage of children considered positive for each antibody: blue (anti-DNA antibodies), red 
(anti-PS antibodies), and purple (anti-PS and anti-DNA antibodies positive).
Clinical Complications
Anti-PS Antibodies Anti-DNA Antibodies
Odds Ratio (95% CI) P value Odds Ratio (95% CI) P value
Prostration 0.93 (0.52, 1.67) 0.813 0.75 (0.43, 1.30) 0.306
Coma 0.59 (0.34, 1.04) 0.067 0.70 (0.41, 1.18) 0.180
Repeated convulsions 0.49 (0.25, 0.96) 0.038 0.79 (0.44, 1.42) 0.434
Deep breathing 1.68 (0.71, 3.97) 0.234 1.20 (0.49, 2.96) 0.692
Acute kidney injury 1.51 (0.85, 2.69) 0.160 2.99 (1.68, 5.31) <0.0001*
Jaundice 1.32 (0.74, 2.36) 0.341 1.90 (1.04, 3.44) 0.034
Shocka — — — —
Abnormal bleeding 0.04 (0.0006, 3.16) 0.151 0.70 (0.07, 7.12) 0.763
Laboratory Measures Beta (95% CI) P value Beta (95% CI) P value
Hemoglobin, g/dL −1.04 (−1.63, −0.44) 0.001* −0.95 (−1.52, −0.38) 0.001*
Lactate, mmol/L 0.88 (−0.12, 1.87) 0.083 1.31 (0.32, 2.30) 0.010
Glucose, mmol/L −0.55 (−1.38, 0.28) 0.192 −0.73 (−1.56, 0.11) 0.087
Parasite Density/uL −24767 (41267) 0.549 −34350 (39542) 0.386
Table 2. Association between a one-unit increase in anti-PS and anti-DNA antibodies and SM criteria. Logistic 
regression for clinical complications and linear regression for laboratory measures. aModel unstable because 
event (n = 1). *Significant following Holm’s correction for multiple comparisons (n = 22).
Anti-PS Antibodies Anti-DNA Antibodies
N rho P value N rho P value
WBC 309 0.135 0.017 309 0.139 0.014
Platelet count 310 −0.049 0.394 310 0.027 0.640
Creatinine 309 0.166 0.003* 309 0.269 <0.0001*
BUN 314 0.239 <0.0001* 314 0.208 0.0002
Total bilirubin 307 0.051 0.370 307 0.028 0.626
Lactate dehydrogenase 305 0.291 <0.0001* 305 0.225 0.0001*
Plasma HRP2 316 0.147 0.009 316 0.002 0.974
Table 3. Correlation of anti-PS and anti-DNA antibodies with measures of malaria severity. Abbreviations: 
white blood cell (WBC), blood urea nitrogen (BUN), histidine rich protein 2 (HRP2). *Significant following 
Holm’s correction for multiple comparisons (n = 14).
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malaria-specific antibodies and disease severity (Table 4). In general, we observed inverse relationships between 
antibody levels and measures of disease severity (e.g. higher bilirubin with reduced AMA-1 levels). However, 
many of these relationships were not significant following adjustment for multiple comparisons.
Relationship between autoantibody levels and clinical recovery and survival. As anti-PS anti-
bodies have previously been shown to promote anemia in a mouse model and correlate with malarial anemia in 
P. falciparum patients14,15, we evaluated if there was a relationship between high autoantibody levels and hospital 
readmission during the study period. Children with high anti-PS antibodies were more likely to be readmitted 
during the study period compared to children without high anti-PS antibodies (35.9% vs. 20.5%, p = 0.032). 
Further, children with high anti-PS antibodies were more likely to be readmitted to the hospital multiple times 
with an adjusted OR of 3.84 (95% CI: 1.44, 10.23, p = 0.007) following correction for age (Table 5). There was no 
relationship between anti-DNA antibodies and hospital readmission (p > 0.05).
Given the relationship between autoantibody levels and disease severity, we evaluated whether autoantibod-
ies were related to in-hospital and post-discharge all-cause two year survival (Table 5). There was no difference 
in autoantibody levels in children who died in-hospital, but there was an increase in median levels of anti-PS 
and anti-DNA antibody levels in children who died post-discharge (p = 0.03 and p = 0.04, respectively). A one 
unit increase in the natural log of anti-PS and anti-DNA antibody levels was associated with increased odds of 
two-year post-discharge mortality (odds ratio (OR) (95% CI): anti-PS, 4.15 (1.03, 16.81), p = 0.046; anti-DNA, 
4.50 (0.87, 23.38), p = 0.073) following adjustment for child age. Although the cause of post-discharge mortality 
was not always ascertained (as a number of children died outside of health centers), all 11 children who died in 
follow up had severe anemia during their initial hospitalization. Two of the follow-up deaths occurred in chil-
dren with CM on admission (both with severe anemia and AKI), and neither had neurologic abnormalities on 
discharge.
Discussion
In the present study we evaluate the relationship between autoimmune antibodies, SM complications, and 
in-hospital and post-discharge mortality in a cohort of Ugandan children with SM and CC. Since autoimmune 
anti-PS antibodies promote malaria-induced anemia in a mouse model and are correlated with malarial anemia 
in adults14,15, we hypothesized that these antibodies may also play a role in children with malarial anemia and 
that other autoimmune antibodies, such as anti-DNA, may contribute to malaria pathogenesis. In this work, 
we demonstrate that in children with SM, anti-PS antibodies are strongly associated with anemia on admis-
sion, post-discharge mortality, and hospital readmissions, and that anti-DNA antibodies are associated with AKI. 
Together, the study findings suggest that in children with SM, anti-PS antibodies may play a role in the develop-
ment of severe anemia and post-discharge morbidity and mortality, and that immune mediated pathways may 
contribute to malaria-related AKI.
Previous studies have shown that anti-PS autoantibodies contribute to anemia in experimental murine mod-
els of malaria by binding to uninfected RBC and promoting their premature clearance from the circulation14. 
Analysis of plasma samples from adults with P. falciparum infections have documented an association between 
anti-PS antibodies andmalarial anemia14,15. This study extends these findings by showing anti-PS and anti-DNA 
autoantibodies are inversely associated with hemoglobin in children with SM during the acute phase of illness. 
Further, we show that children positive for anti-PS antibodies on admission are at risk for multiple hospital read-
missions during follow-up. These data are consistent with previous reports describing an association of anti-RBC 
autoantibodies and anemia in P. vivax25,26, although in these studies only antibodies recognizing proteins, not 
lipids or nucleic acids (such as PS and DNA), were analyzed.
In mouse models of malaria, infected, but also uninfected RBC, expose PS in their surface14,27, which is rec-
ognized by anti-PS antibodies, contributing to anemia14. Our knowledge of this mechanism in human patients is 
more limited, but an inverse correlation of anti-PS antibodies and hemoglobin levels was described in malarial 
AMA-1 MSP-1 CSP GLURP
N rho P value N rho P value N rho
P 
value N rho
P 
value
Hemoglobin 254 −0.045 0.477 254 0.156 0.013 254 −0.052 0.410 254 0.004 0.955
WBC 247 −0.007 0.910 247 −0.035 0.589 247 0.085 0.186 247 0.183 0.004
Platelet count 248 −0.098 0.124 248 −0.232 0.0002* 248 −0.074 0.248 248 −0.032 0.617
Creatinine 248 −0.082 0.195 248 −0.017 0.795 248 0.133 0.037 248 0.101 0.114
BUN 254 −0.082 0.195 254 −0.078 0.214 254 0.080 0.203 254 −0.047 0.461
Total bilirubin 248 −0.250 0.0001* 248 −0.143 0.0246 248 −0.045 0.486 248 −0.063 0.323
Lactate dehydrogenase 247 −0.132 0.038 247 −0.017 0.006 247 0.013 0.846 247 −0.100 0.118
Plasma HRP 2 254 −0.156 0.013 254 −0.040 0.432 254 −0.028 0.662 254 −0.144 0.022
eGFR 247 0.140 0.028 247 0.035 0.580 247 −0.124 0.051 247 −0.042 0.509
Table 4. Correlation between malaria antibodies and measures of malaria severity. Abbreviations: apical 
membrane antigen-1 (AMA-1), merozoite surface protein-1 (MSP-1), circumsporozoite protein (CSP), 
glutamate rich protein (GLURP), white blood cell (WBC), blood urea nitrogen (BUN), histidine rich protein 
2 (HRP2), estimated glomerular filtration rate (eGFR). *Significant following Holm’s correction for multiple 
comparisons (n = 36).
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anemia14,15. Since in vitro treatment of RBC with artesunate increases PS translocation to the RBC surface28, it is 
possible anti-PS antibodies binding to PS on the surface of RBC may be an additional mechanism contributing 
to anemia following artesunate treatment29. Additional studies are needed to determine: (i) how levels of anti-PS 
autoantibodies change over infection; (ii) whether anti-PS antibodies may contribute to recurrent anemia in 
children with repeated malaria infections; and (iii) whether anti-PS autoantibodies accelerate the removal of RBC 
following parenteral treatment with artesunate.
We observed a correlation between lactate dehydrogenase (LDH) and autoantibody levels, suggesting RBC 
lysis may be mediated by autoantibodies. Alternatively, it is possible hemolysis enhances autoantibody production 
through immune activation and exposure to self-antigens. Additional studies are needed to delineate whether 
RBC hemolysis is mediated by complement fixation on RBC-bound anti-PS antibodies, or whether hemolysis 
triggers the generation of autoantibodies.
Anti-DNA antibodies also correlated with anemia in children with SM. This association may be explained 
by the observations that DNA is abundant in the circulation of malaria patients30 and that cell-free DNA binds 
to uninfected red blood cells31. RBC-bound DNA could be targeted by infection-induced anti-DNA antibodies 
promoting their clearance and enhancing anemia. Cell-free DNA in malaria patients declines upon resolution32, 
which could explain the lack of correlation of anti-DNA antibodies with hospital readmission.
In this study anti-DNA antibodies were strongly associated with the presence and severity of AKI. Previous 
studies in children with SM suggest the etiology of AKI at presentation is largely related to reduced renal per-
fusion19 as a result of hypovolemia and impaired microvascular perfusion from parasitized RBC cytoadhesion 
to the endothelium. We observed an inverse relationship between eGFR and anti-DNA and anti-PS antibodies 
during SM, raising questions on whether reduced autoantibody clearance in AKI leads to increases in circulating 
autoantibodies. The MHC class 1-like Fc receptor (FcRn) is one receptor important in maintaining serum levels 
of albumin and IgG, contributing to the long half-life of IgG. However, podocytes and proximal tubule epithe-
lium in the kidney express FcRn that have been shown to promote IgG clearance from the glomerular basement 
membrane33. Additionally, other receptors involved in antibody removal such as complement receptor 1 (CR1/
CD35) are expressed on podocytes34 and down regulated in other cell types during malaria35. While it is possible 
that reduced GFR may lead to altered renal handling of IgG and affect levels of circulating autoantibodies, we did 
not observe any relationship with total IgG against malaria antigens AMA-1, MSP-1, CSP, or GLURP and any 
measures of renal function (AKI, creatinine, BUN, or eGFR). These data suggest changes in IgG metabolism are 
not responsible for the increase in autoantibodies.
Anti-DNA antibodies are associated with glomerulonephritis and AKI in SLE through a variety of mecha-
nisms including: (a) DNA immune complex (IC) entrapment in glomerular basement membranes, (b) non-DNA 
antigen crossreactivity, (c) binding to apoptoic cellular debris in the glomerulus and acting as “a planted antigen” 
and/or (d) anti-DNA binding to kidney cells including podocytes, endothelial cells and/or proximal tubule cells 
leading to renal injury36. P. malariae can lead to a nephrotic syndrome associated with a membrano-proliferative 
glomerulonephritis with deposits of IgM, IgG and C3 in mesangial and subendothelial tissue37. However, the 
pathogenesis of P. falciparum appears to be different and the role of auto-antibodies and IC in kidney pathogen-
esis during P. falciparum remains unclear. Even if it is well-documented that there are increases in circulating 
DNA and anti-DNA that form IC in the circulation32, evidence of IC deposition in kidneys of patients with P. 
falciparum is inconsistent38–40. The relationship between anti-DNA autoantibodies and glomerulonephritis has 
not been systematically investigated using immunofluorescent labeling of immunoglobulins and complement to 
detect and characterize glomerulonephritis in renal biopsies of surviving patients. Together, these results indi-
cate that an immune mediated pathway, possibly an immune-mediated glomerulonephritis, similar to what is 
observed with SLE nephritis, could contribute to P. falciparum malaria-associated AKI41. We further speculate 
that anti-DNA autoantibodies may lead to proximal tubular cell injury and acute tubular necrosis in the absence 
of glomerulonephritis.
This study has several strengths. We were able to measure autoantibodies in a well characterized population of 
Ugandan children with SM and compare autoantibodies with malaria-specific antibodies. The finding of a strong 
association between anti-DNA autoantibodies and AKI (defined using established KDIGO criteria and using CC 
Anti-PS Antibodies Anti-DNA Antibodies
Odds Ratio (95% CI) P value Odds Ratio (95% CI) P value
Autoantibody levels
In-hospital mortality 0.81 (0.38, 1.73) 0.587 0.63 (0.22, 1.82) 0.393
Post-discharge mortality 4.15 (1.03, 16.81) 0.046 4.50 (0.87, 23.38) 0.073
Hospital readmission 1.40 (0.89, 2.22) 0.147 0.78 (0.43, 1.42) 0.425
Multiple readmissions 1.88 (0.88, 3.99) 0.102 1.03 (0.40, 2.68) 0.944
High autoantibody levels
In-hospital mortality 0.39 (0.05, 3.01) 0.366 0.40 (0.05, 3.10) 0.382
Post-discharge mortality 3.48 (0.61, 19.73) 0.159 3.67 (0.64, 20.92) 0.143
Hospital readmission 1.95 (0.94, 4.06) 0.074 0.38 (0.13, 1.10) 0.075
Multiple readmissions 3.84 (1.44, 10.23) 0.007 0.33 (0.04, 2.50) 0.280
Table 5. Relationship between anti-PS and anti-DNA antibodies and outcomes. aLogistic regression model 
adjusting for child age. *Significant following Holm’s correction for multiple comparisons (n = 16).
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to define baseline creatinine), that was not present for anti-PS antibodies or malaria-specific antibodies, suggests 
a mechanistic link between anti-DNA antibodies and AKI. Further, the prospective design enabled us to evaluate 
the relationship between autoantibodies, post-discharge mortality, and risk of subsequent hospitalization.
This study has limitations. We included children with two manifestations of severe malaria and therefore can-
not comment on the generalizability of these findings to other manifestations of severe or uncomplicated malaria. 
As we did not collect longitudinal samples, we cannot draw conclusions on how autoantibody levels change 
following treatment and whether there are clinical consequences associated with post-treatment autoantibody 
levels. Apart from the assessment of hemoglobin in the urine, no additional urinalysis was conducted and urine 
was not stored. Quantification of blood and protein in the urine and renal biopsy findings will be needed to better 
characterize AKI in SM.
In summary, we report elevations in anti-DNA and anti-PS autoantibodies in SM. Consistent with another 
study in malarial anemia14,15, we show a relationship between autoantibodies and anemia, this time in children 
with acute severe malaria in an endemic area. We also show that children testing positive for anti-PS antibodies 
were more likely to be readmitted to the hospital and readmitted multiple times compared to children negative 
for anti-PS antibodies. We also report a relationship between anti-DNA antibodies and the presence and severity 
of AKI. Additional studies are needed to evaluate the impact of malaria treatment on autoantibody levels, and 
to assess the relationship between post-treatment autoantibodies and long-term complications of severe malaria 
including recurrent hospitalizations for severe anemia, death, and chronic kidney disease.
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